Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma

Phosphatidylinositol-3-kinase (PI3K) inhibitors have shown activity in relapsed or refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). PI3K inhibitors have been hampered by poor long-term tolerability and toxicity, which interfere with continuous use. Umbralisib, a dual inhibitor of PI3Kδ/casein...

Full description

Saved in:
Bibliographic Details
Published in:J Clin Oncol
Main Authors: Fowler, Nathan H., Samaniego, Felipe, Jurczak, Wojciech, Ghosh, Nilanjan, Derenzini, Enrico, Reeves, James A., Knopińska-Posłuszny, Wanda, Cheah, Chan Y., Phillips, Tycel, Lech-Maranda, Ewa, Cheson, Bruce D., Caimi, Paolo F., Grosicki, Sebastian, Leslie, Lori A., Chavez, Julio C., Fonseca, Gustavo, Babu, Sunil, Hodson, Daniel J., Shao, Spencer H., Burke, John M., Sharman, Jeff P., Law, Jennie Y., Pagel, John M., Miskin, Hari P., Sportelli, Peter, O'Connor, Owen A., Weiss, Michael S., Zinzani, Pier Luigi
Format: Artigo
Language:Inglês
Published: Wolters Kluwer Health 2021
Subjects:
RAPID COMMUNICATIONS
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8148421/
https://ncbi.nlm.nih.gov/pubmed/33683917
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.03433
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items